Wegovy-maker Novo Nordisk to slash 9,000 jobs as competition heats up:
Novo Nordisk , the maker of blockbuster weight-loss drug Wegovy, will cut 9,000 jobs or 11 ...
reuters.com/business/wegovy-maker-novo-nordisk-slash-9000-jobs-competition-heats-up-2025-09-10/
Photo: reuters.com · view article
Novo Nordisk Cuts 9,000 Jobs Amid Rising CompetitionThe Danish pharma firm aims to save $1.3 billion annually as US rival Eli Lilly intensifies market pressure in 2025.
Key FactsSep 10, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- Novo Nordisk will eliminate 9,000 positions, equal to 11.5% of its workforce, including 5,000 cuts in Denmark.
- This restructuring is expected to save about $1.3 billion per year and streamline decision-making processes.
- New CEO Mike Doustdar plans to foster a performance-driven culture and prioritize investments in key therapy areas.
- The company now forecasts operating profit growth between 4% and 10% for 2025, down from earlier estimates.
Sometimes the hardest decisions are the right ones for the future we're building.— Mike Doustdar, CEO of Novo Nordisk, discussing the necessity of tough decisions for the long-term success of the company.
Story Details
| Last Updated | |
| Total Articles | 39 |
Main Topics
News on this topic
Ozempic giant Novo Nordisk to cut 9,000 jobs: The Danish drugmaker faces strong competition from Eli Lilly in the obesity drugs market.
politico.eu/article/novo-nordisk-to-cut-9000-jobs/
Danish pharmaceutical giant Novo Nordisk to cut 5,000 jobs in Denmark: Pharmaceutical giant Novo Nordisk announced on Wednesday that it would cut 11 percent of ...
thelocal.dk/20250910/danish-pharmaceutical-giant-novo-nordisk-to-cut-5000-jobs-in-denmark
Wegovy maker Novo Nordisk to slash thousands of jobs: The layoffs come amid sluggish sales as competition heats up in the weight-loss drug market.
aljazeera.com/economy/2025/9/10/wegovy-maker-novo-nordisk-to-slash-thousands-of-jobs
More articles on this subject
Previous
Wegovy and Ozempic maker to cut 9,000 jobs amid stiff competition from Eli Lilly: Novo Nordisk, the maker of weight loss drug Wegovy, will lay off about 9 ...
edition.cnn.com/2025/09/10/business/novo-nordisk-layoffs-intl
Ozempic Maker Novo Nordisk to Cut 9,000 Jobs: The Danish drugmaker said it needed to streamline operations and become more agile, as it faces a more competitive ...
nytimes.com/2025/09/10/business/novo-nordisk-job-cuts-ozempic.html
Wegovy-maker Novo Nordisk to slash 9,000 jobs as competition heats up: Novo, which was at one point last year Europe's most valuable listed company ...
khaleejtimes.com/business/wegovy-maker-novo-nordisk-to-slash-9000-jobs-as-competition-heats-up
Ozempic-maker Novo Nordisk to cut 9,000 jobs: The Danish firm, which also produces Wegovy, has warned of increased pressure from "knock-off" drugs.
bbc.com/news/articles/c8d79pez6g2o
Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies: The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly ...
euronews.com/business/2025/09/10/novo-nordisk-to-cut-9000-jobs-as-eli-lilly-competition-intensifies
Ozempic maker to cut thousands of jobs: The Danish pharmaceutical company will reduce its 78,400-person workforce by approximately 9 ...
foxbusiness.com/lifestyle/ozempic-maker-cut-thousands-jobs
Ozempic maker Novo Nordisk slashes 9 000 jobs in fierce weight-loss drug battle: The restructuring, including the largest layoff in Denmark’s history ...
news24.com/business/companies/ozempic-maker-novo-nordisk-slashes-9-000-jobs-in-fierce-weight-loss-drug-battle-20250910-0923
Paid articlePaywall
Novo Nordisk to cut 9,000 jobs and lowers profit forecast: Novo Nordisk will cut 9,000 jobs globally, including 5,000 in Denmark, amid slowing growth and ...
helsinkitimes.fi/business/27882-novo-nordisk-to-cut-9-000-jobs-and-lowers-profit-forecast.html
Ozempic maker Novo Nordisk is cutting 9,000 jobs: Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9 ...
apnews.com/article/wegovy-novo-nordisk-ozempic-obesity-denmark-357fd9cbef29b324dfb059f35dc5ff6a
Ozempic-maker Novo Nordisk to cut 9,000 jobs in restructuring: Novo, which has 78,400 positions globally, said about 5,000 of the job cuts will be in its native ...
straitstimes.com/business/companies-markets/ozempic-maker-novo-nordisk-to-cut-9000-jobs-in-restructuring
eNCA Sep 10 25
Ozempic maker Novo Nordisk to cut 9,000 global jobs
enca.com/business/ozempic-maker-novo-nordisk-cut-9000-global-jobs
Ozempic-maker Novo Nordisk to cut 9,000 jobs: Novo Nordisk A/S will slash 9,000 jobs globally and cut its profit forecast for the third time this year.
thestar.com/news/world/ozempic-maker-novo-nordisk-to-cut-9-000-jobs/article_264cd7f9-66c8-5def-bf48-cc3492168853.html
Paid articlePaywall
The Globe and Mail Sep 10 25
Novo Nordisk cuts 9,000 jobs as it fends off competition in weight-loss drugs : The Danish company faces slowing momentum in its once-booming obesity and ...
theglobeandmail.com/business/international-business/article-novo-nordisk-wegovy-layoffs-obesity-diabetes-eli-lilly/
Novo Nordisk to Cut 11% of Workforce as New CEO Slashes Forecast: Novo Nordisk A/S will slash 9,000 jobs globally and cut its profit forecast for the third time ...
bloomberg.com/news/articles/2025-09-10/novo-nordisk-will-cut-9-000-jobs-globally-to-save-1-3-billion
Paid articlePaywall
CNA Sep 10 25
Ozempic maker Novo Nordisk to cut 9,000 global jobs: COPENHAGEN: Danish pharmaceutical giant Novo Nordisk announced on Wednesday (Sep 10) that it would cut 11 ...
channelnewsasia.com/business/ozempic-maker-novo-nordisk-cut-9000-global-jobs-5341801
EWN Sep 10 25
Ozempic maker Novo Nordisk to cut 9,000 global jobs: The drug maker said in a statement it would save eight billion kroner ($1.3 billion) by slashing 9,000 jobs ...
ewn.co.za/2025/09/10/ozempic-maker-novo-nordisk-to-cut-9-000-global-jobs
Ozempic maker Novo Nordisk to cut 9,000 jobs amid increased competition: Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli ...
theguardian.com/business/2025/sep/10/ozempic-maker-novo-nordisk-to-cut-9000-jobs-amid-increased-competition
Wegovy-maker Novo Nordisk to slash 9,000 jobs as competition heats up: Novo Nordisk , the maker of blockbuster weight-loss drug Wegovy, will cut 9,000 jobs or 11 ...
reuters.com/business/wegovy-maker-novo-nordisk-slash-9000-jobs-competition-heats-up-2025-09-10/
Novo Nordisk to cut 11% of jobs
businesspost.ie/article/novo-nordisk-to-cut-11-of-jobs/
Paid articlePaywall
Novo Nordisk to cut 9,000 jobs as it slashes profit forecast: Danish drugmaker warns over slowing growth as Ozempic and Wegovy producer faces pressure from US ...
ft.com/content/2d610c6e-f392-48d4-a10b-e36d81b1f2b4
Paid articlePaywall
Wegovy-maker Novo Nordisk to cut around 9,000 jobs: Novo Nordisk, which produces Wegovy and Ozempic, said roughly 9,000 roles would be cut, with 5 ...
cnbc.com/2025/09/10/wegovy-maker-novo-nordisk-to-cut-around-9000-jobs.html
Next
Similar to This
Previous
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
cnbc.com/2026/09/14/novo-nordisk-rebrands-to-novo-ceo-mike-doustdar.html
It created Ozempic. Now this company has run into major problems: The maker of Ozempic is facing stiff competition from rival obesity drug companies ...
smh.com.au/business/companies/it-created-ozempic-now-this-company-has-run-into-major-problems-20260204-p5nzj8.html
Novo Nordisk rolls out $349 Wegovy cash price ahead of plan: Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a ...
reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-rolls-out-349-wegovy-cash-price-ahead-plan-2025-11-17/
Novo Nordisk strikes US Medicare price deal: Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide ...
reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-accepts-ozempic-wegovy-rybelsus-prices-us-medicare-negotiations-2025-11-05/
Ozempic maker Novo Nordisk cuts sales and profit forecasts again: Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in ...
theguardian.com/business/2025/nov/05/ozempic-maker-novo-nordisk-cuts-sales-profit-forecasts-again-wegovy
Novo Nordisk buys US biotech company Akero - | Deutsches Ärzteblatt
aerzteblatt.de/news/novo-nordisk-kauft-us-biotech-firma-akero-eb00f355-99bd-4ac8-82cf-417332f535f0
Novo Nordisk Layoffs: How Ozempic Maker Faces Pressure From Copycats, Eli Lilly: For a while, Danish drugmaker Novo Nordisk A/S looked unstoppable.
bloomberg.com/news/articles/2025-10-01/novo-nordisk-layoffs-how-ozempic-maker-faces-pressure-from-copycats-eli-lilly
Paid articlePaywall
The Inventor of Ozempic Is Suddenly Sacking Huge Numbers of Employees: Novo Nordisk, the drugmaker behind Ozempic, is laying off thousands of workers as it ...
futurism.com/neoscope/novo-nordisk-ozempic-layoffs
Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts
reuters.com/business/world-at-work/novo-nordisk-cuts-us-obesity-education-team-layoffs-begin-say-sources-online-2025-09-18/
The Inventor of Ozempic Is Suddenly Sacking Huge Numbers of Employees: Novo Nordisk, the drugmaker behind Ozempic, is laying off thousands of workers as it ...
futurism.com/neoscope/novo-nordisk-ozempic-layoffs
Riding high on Wegovy, Novo doubled its workforce. Now layoffs loom: As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed ...
reuters.com/business/finance/riding-high-wegovy-novo-doubled-its-workforce-now-layoffs-loom-2025-08-21/
Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply: Fierce competition and threat of Trump tariffs lead to Danish company cutting costs
theguardian.com/business/2025/aug/06/sales-of-novo-nordisk-diabetes-drugs-including-ozempic-slow-sharply
OpinionYour Wegovy May Pay for Itself: The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.
wsj.com/opinion/your-wegovy-may-pay-for-itself-medication-prices-weight-loss-cbbd1bf3
Paid articlePaywall
Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding: Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by ...
npr.org/sections/shots-health-news/2025/07/29/nx-s1-5484143/drugmaker-novo-nordisk-slashes-wegovy-sales-forecasts-blaming-compounding
In Ozempic’s home town they fear two things: a new set of tariffs, and a company in Kinsale
irishtimes.com/world/europe/2025/07/28/in-ozempics-home-town-they-fear-two-things-a-new-set-of-tariffs-and-a-company-in-kinsale/
Major insurance changes are coming to GLP-1 drugs for weight loss. Here’s how that could affect patients
cnn.com/2025/07/01/health/zepbound-wegovy-insurance-cvs-bcbs-weight-loss
Use of weight-loss drug Wegovy up 50% among US teens: American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors ...
timeslive.co.za/news/sci-tech/2025-06-04-use-of-weight-loss-drug-wegovy-up-50-among-us-teens/
Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug: Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 ...
reuters.com/business/healthcare-pharmaceuticals/eli-lilly-acquire-privately-held-siteone-2025-05-27/
Novo Nordisk hopes to see US Wegovy sales recover soon: Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover ...
reuters.com/business/healthcare-pharmaceuticals/obesity-drugmaker-novo-nordisk-cuts-2025-outlook-posts-q1-profit-above-forecast-2025-05-07/
Key FactsNovo Nordisk Optimistic Despite Sales Forecast Cuts
May 7, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- Novo Nordisk anticipates a recovery in Wegovy sales in the U.S. following the FDA's ban on compound copycats.
- Sales forecasts for 2025 have been lowered due to market impact from compounding pharmacies.
- Novo recently launched Wegovy in three additional countries and plans to accelerate further launches.
- Quarterly profits exceeded analyst expectations while shares rose by 4%.
It's unprecedented in our industry to have very large volumes of products flowing to patients that are not approved.— Lars Fruergaard Jorgensen, CEO of Novo Nordisk, discussing the impact of unapproved medications on the company's growth.
Next